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Gary L. Schaer, MD,y Chunxiang Zhang, MD, PHDzSEE PAGE 2314V ascular responses to angioplasty includeelastic recoil, dissection, and neointimal for-mation. Stent implantation is superior to
balloon angioplasty alone, because it successfully
prevents and/or treats vascular elastic recoil and
dissection. However, bare-metal stents promote neo-
intimal hyperplasia, the major cause of in-stent reste-
nosis. The development of drug-eluting stents (DES)
has been one of the major revolutions in the ﬁeld of
interventional cardiology (1). By inhibiting neointi-
mal hyperplasia, DES dramatically reduce restenosis
and target vessel revascularization compared with
bare-metal stents.
However, the drugs that elute from the current
generation of DES are nonselective. In addition to
inhibiting smooth muscle cell proliferation and
migration, which is their therapeutic effect, they also
suppress endothelial cell growth and mobility, which
may contribute to adverse consequences such as
delayed or impaired re-endothelialization, the need
for prolonged dual antiplatelet therapy, and stent
thrombosis (2). Thus, despite the clinical beneﬁts
of DES in reducing restenosis, there continue to
be concerns about the long-term risk of myocardial
infarction and cardiac death. Reducing these risks
presents a key challenge to both the clinical cardiol-
ogist and basic vascular biologist, and represents a
major focus of interventional cardiology research as
future generations of DES are developed.*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the yDivision of Cardiology, Cardiovascular Research Center, Rush
University Medical Center, Chicago, Illinois; and the zDepartment of
Pharmacology, Cardiovascular Research Center, Rush University Medical
Center, Chicago, Illinois. Both authors have reported that they
have no relationships relevant to the contents of this paper to
disclose.Micro-ribonucleic acids (miRNAs), with tremen-
dous biological functions, are a class of endoge-
nous, small, noncoding RNAs that directly regulate
more than 30% of genes in a cell. Recent studies
have demonstrated that miRNAs play critical roles
in vascular integrity, inﬂammation, and disease (3).
However, direct evidence has been missing as to
whether miRNAs are involved in restenosis in sten-
ted arteries and whether miRNA modulators could
be used as novel eluting drugs in vascular stents.In this issue of the Journal, McDonald et al. (4)
report that a decrease in miRNA-21 (miR-21)
reduces in-stent restenosis and inﬂammation in
stented arteries. Using microarray analysis, they
identiﬁed for the ﬁrst time that multiple miRNAs
were aberrantly expressed in stented pig arteries.
Among them, a group of inﬂammatory miRNAs,
including miR-21, were increased. Strong activation
of miR-21 was also detected in a human coronary
artery after DES implantation. Using a mouse
vascular stent model, they then found that the
knockout of miR-21 attenuated neointimal forma-
tion post-stenting via modulating smooth muscle
cell functions and the inﬂammatory response as
shown by enhanced levels of anti-inﬂammatory M2
macrophages.
There are several important aspects of this study.
First, large animal models, such as the pig stent
model, are an important bridge between small an-
imal models and human stent implantation. Al-
though miRNA proﬁles in arteries after angioplasty
have been well studied in small animals, such as
rats and mice, to the best of our knowledge, this is
the ﬁrst study to show the expression signatures of
miRNAs in both normal and stented pig arteries.
Second, although the biological roles of miR-21
in smooth muscle cells have been well-studied
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2329in balloon-injured vascular walls (5), its roles in
the inﬂammatory response in stented arteries and
in-stent stenosis have not been reported. In addi-
tion, using miRNA knockout mice to study the
vascular response to stenting stands as an innova-
tive aspect of this study. Moreover, the demon-
stration of miR-21 expression in a stented human
coronary artery is an important translational feature
of the work by McDonald et al. (4), although
this result should be veriﬁed by additional human
samples.
We have identiﬁed some weaknesses of the study.
First, the miRNA microarray used was intended for
human miRNAs. Although this human array works
well for conserved human/pig miRNAs on pig sam-
ples, it performs less well for miRNAs that are not
conserved. Second, miR-21 is broadly expressed in all
the cells related to vascular responses after stent
implantation such as endothelial cells, platelets,
smooth muscle cells, and inﬂammatory cells. The
effects of miR-21 on platelet activation and endo-
thelial cell recovery should also be tested, in addi-
tion to its effects on smooth muscle cells and
inﬂammatory cells. At the tissue level, re-
endothelialization should be determined in addition
to neointimal formation. It should be noted that,
although the miRNA knockout mouse is an out-
standing approach to study miRNAs after vascular
stenting, we should keep in mind that knockout mice
may have compensative responses. Thus, a pharma-
cological approach in addition to a genetic approach
is optimal.
To date, miRNAs are known to be critical
regulators for all the cellular events after angio-
plasty and stent implantation, including endothelial
cell recovery, smooth muscle cell migration and
proliferation, platelet activation, and leukocyte
activation. Importantly, the expression and biolog-
ical functions of miRNAs are cell-speciﬁc. For
example, miR-145 is highly expressed in vascular
smooth muscle cells, but not expressed in other
vascular cells (6). Also, miR-145 has a strong effect
on smooth muscle cells, but not on endothelial
cells. More excitingly, miRNA could have an oppo-
site cellular effect on different vascular cells. For
example, miR-221 and miR-222 have effects of pro-
proliferation, promigration, and antiapoptosis on
smooth muscle cells, but have antiproliferative,
antimigration, and proapoptotic effects on vascular
endothelial cells (7). All the previously noted fea-
tures of miRNAs suggest that miRNA modulators
could be used as novel eluting drugs in vascular
stents. Indeed, we have shown that inhibition ofmiR-221 and miR-222 could reduce vascular neo-
intimal formation, but enhance re-endothelialization
after angioplasty (7). The vascular effects of miR-221
and miR-222 modulator match very well with the
requirements of novel eluting drugs in vascular
stents.
miRNAs could be successfully upregulated by
their pre-miRNAs or miRNA mimics both in cultured
cells in vitro and in injured arteries in vivo via local
delivery with transfection reagents. On the other
hand, miRNA expression could be successfully down-
regulated by many types of miRNA inhibitors. For
long-term miRNA modulation, miRNA expression
could be regulated by virus vectors (adenovirus,
lentivirus, or adeno-associated virus) expressing
miRNAs or their inhibitors. To date, the coating
method of miRNA modulators on stents and their
delivery and/or release into vascular walls via stents
have not been established.
Another challenge to the use of miRNA modula-
tors as eluting drugs is the selection of a thera-
peutic strategy. It is well known that multiple
miRNAs may participate in the vascular responses
post-stenting. However, each miRNA may only have
a modest effect. Thus, multiple modulators or a
“therapeutic cocktail” should be selected and their
interactions characterized before they are used in
vascular stents. Although the biological functions
of miRNAs in vascular smooth muscle cells and
endothelial cells after angioplasty are well studied,
more research is needed on the role of miRNAs in
platelets and leukocytes after angioplasty. Obvi-
ously, more stented human vessels should be used
for miRNA studies in the future. Finally, the ther-
apeutic effects of vascular stents with miRNA
modulators should be clariﬁed in both small and
large animals as a prelude to their use in clinical
trials.
Although we still have a long way to go before
miRNA modulators are clinically used as novel
eluting drugs in vascular stents, an increasing body
of evidence suggests that DES with miRNA modula-
tors (a miR-stent) may overcome some of the pitfalls
of current vascular stents. Thus, the genetic stent
may represent the next generation of vascular
stents.
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